Aurobindo Pharma Q2 net profit rises 8.6% to Rs 817 crore in Q2FY25
Aurobindo Pharma witnessed an 8.6% YoY increase in net profit, reaching Rs 817 crore in Q2 FY25, driven by robust sales in Europe and growth markets. Despite a dip in US formulations revenue, the company's overall revenue rose by 8% YoY.
By Viswanath Pilla, ET Bureau |
Agencies
Aurobindo Pharma on Saturday reported 8.6% year-on-year (YoY) rise in net profit to Rs 817 crore in the second quarter ended September 2023, led by strong sales from the Europe and growth markets.
The company posted net profit of Rs 752 crore in the corresponding quarter of previous year. On a quarter-on-quarter (QoQ) basis the net profit declined 11%.
Revenue from operations increased by 8% YoY to Rs 7,796 crore in Q2FY25
On a QoQ basis revenue rose 3%.
The earnings before interest, tax, depreciation and ammortisation (EBITDA) before forex and other income rose 11.6% to Rs 1566 crore. The EBITDA margin for the quarter increased 65 basis points YoY to 20.1%.
US formulations revenue that constitute 45.3% increased 4.3% YoY to Rs 3530 crore. Europe formulation revenue which contributes 27% of revenues stood at Rs 2105 crore, with YoY increase of 19%. mar
Growth Markets revenue grew by 44% YoY to Rs 812 crore, while the antiretroviral revenue declined 22.8% YoY to Rs 193 crore.
The active pharmaceutical ingredient (API) revenue dropped 0.9% YoY to Rs 1,156 crore.
The research & development (R&D) spend stood at Rs. 410 crore, constituting about 5.3% of revenues.
"While profitability saw a slight dip, primarily due to the transient nature of certain business activities, our underlying performance remains strong," said K. Nithyananda Reddy, vice-chairman and managing director.
"With a solid foundation and ongoing operational improvements, we are confident of maintaining our growth trajectory and achieving our strategic objectives for the year," Reddy added.
The company posted net profit of Rs 752 crore in the corresponding quarter of previous year. On a quarter-on-quarter (QoQ) basis the net profit declined 11%.
Revenue from operations increased by 8% YoY to Rs 7,796 crore in Q2FY25
On a QoQ basis revenue rose 3%.
The earnings before interest, tax, depreciation and ammortisation (EBITDA) before forex and other income rose 11.6% to Rs 1566 crore. The EBITDA margin for the quarter increased 65 basis points YoY to 20.1%.
US formulations revenue that constitute 45.3% increased 4.3% YoY to Rs 3530 crore. Europe formulation revenue which contributes 27% of revenues stood at Rs 2105 crore, with YoY increase of 19%. mar
ADVERTISEMENT
Growth Markets revenue grew by 44% YoY to Rs 812 crore, while the antiretroviral revenue declined 22.8% YoY to Rs 193 crore.
The active pharmaceutical ingredient (API) revenue dropped 0.9% YoY to Rs 1,156 crore.
The research & development (R&D) spend stood at Rs. 410 crore, constituting about 5.3% of revenues.
"While profitability saw a slight dip, primarily due to the transient nature of certain business activities, our underlying performance remains strong," said K. Nithyananda Reddy, vice-chairman and managing director.
ADVERTISEMENT
"With a solid foundation and ongoing operational improvements, we are confident of maintaining our growth trajectory and achieving our strategic objectives for the year," Reddy added.
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
Related Articles
Aurobindo Pharma Q2 Results: Net profit soars 84% to Rs 752 crore on strong overseas demandADVERTISEMENT
